loading...| Preferred Name |
Nabumetone |
|
| Synonyms |
4-(6-Methoxy-2-naphthalenyl)-2-butanone NABUMETONE Nabumetone Relafen |
|
| Definitions |
A naphthylalkanone and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Nabumetone is a prodrug that upon hepatic catalysis converts into the active moiety 6-methoxy-2-naphthylacetic acid (6MNA). 6MNA inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of nabumetone. The formation of thromboxane A2, by thromboxane synthase, is also decreased and results in an inhibition of platelet aggregation. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C47627 |
|
| CAS_Registry |
42924-53-8 |
|
| Chemical_Formula |
C15H16O2 |
|
| code |
C47627 |
|
| Concept_In_Subset | ||
| Contributing_Source |
FDA |
|
| DEFINITION |
A naphthylalkanone and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Nabumetone is a prodrug that upon hepatic catalysis converts into the active moiety 6-methoxy-2-naphthylacetic acid (6MNA). 6MNA inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of nabumetone. The formation of thromboxane A2, by thromboxane synthase, is also decreased and results in an inhibition of platelet aggregation. |
|
| FDA_UNII_Code |
LW0TIW155Z |
|
| FULL_SYN |
4-(6-Methoxy-2-naphthalenyl)-2-butanone NABUMETONE Nabumetone Relafen |
|
| label |
Nabumetone |
|
| Legacy Concept Name |
Nabumetone |
|
| Preferred_Name |
Nabumetone |
|
| prefixIRI |
Thesaurus:C47627 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0701331 |
|
| subClassOf |